嵌合抗原受体T细胞（CAR-T）疗法：确定接受过大量预处理的多发性骨髓瘤患者的无进展生存期获益情况。 - Suppr

Suppr

超能文献

CAR-T treatment: Determining the progression-free survival gain in patients with heavily pretreated multiple myeloma.

作者信息

Messori Andrea

机构信息

HTA Unit Regional Health Service Florence Italy.

出版信息

EJHaem. 2020 Jul 13;1(1):371-373. doi: 10.1002/jha2.63. eCollection 2020 Jul.

DOI:10.1002/jha2.63

PMID:35847745

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9176024/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7f6/9176024/426237a2e1b6/JHA2-1-371-g001.jpg

相似文献

CAR-T treatment: Determining the progression-free survival gain in patients with heavily pretreated multiple myeloma.嵌合抗原受体T细胞（CAR-T）疗法：确定接受过大量预处理的多发性骨髓瘤患者的无进展生存期获益情况。

EJHaem. 2020 Jul 13;1(1):371-373. doi: 10.1002/jha2.63. eCollection 2020 Jul.

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.BCMA CAR-T 细胞疗法在多发性骨髓瘤中的安全性和临床疗效。

J Hematol Oncol. 2020 Dec 3;13(1):164. doi: 10.1186/s13045-020-01001-1.

Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.泊马度胺、卡非佐米和达雷妥尤单抗用于治疗美国多次接受治疗的复发难治性多发性骨髓瘤患者的成本效益

Clin Ther. 2017 Oct;39(10):1986-2005.e5. doi: 10.1016/j.clinthera.2017.08.010. Epub 2017 Sep 28.

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.西达基奥仑赛，一种针对 B 细胞成熟抗原的嵌合抗原受体 T 细胞疗法，用于治疗复发或难治性多发性骨髓瘤患者（CARTITUDE-1）：一项 1b/2 期开放标签研究。

Lancet. 2021 Jul 24;398(10297):314-324. doi: 10.1016/S0140-6736(21)00933-8. Epub 2021 Jun 24.

Clinical experience of CAR T cells for multiple myeloma.嵌合抗原受体T细胞治疗多发性骨髓瘤的临床经验

Best Pract Res Clin Haematol. 2021 Sep;34(3):101306. doi: 10.1016/j.beha.2021.101306. Epub 2021 Aug 28.

[CAR-T cells immunotherapy in multiple myeloma: Present and future].[嵌合抗原受体T细胞免疫疗法在多发性骨髓瘤中的现状与未来]

Bull Cancer. 2021 Oct;108(10S):S65-S72. doi: 10.1016/j.bulcan.2021.09.005.

The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma.idecabtagene vicleucel在多次预处理的难治性多发性骨髓瘤患者中的作用。

Ther Adv Hematol. 2021 May 31;12:20406207211019622. doi: 10.1177/20406207211019622. eCollection 2021.

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.伊达比星脂质体注射用多柔比星治疗复发/难治性多发性骨髓瘤

N Engl J Med. 2021 Feb 25;384(8):705-716. doi: 10.1056/NEJMoa2024850.

B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis.嵌合抗原受体 T 细胞治疗复发或难治性多发性骨髓瘤的 B 细胞成熟抗原特异性：一项荟萃分析。

Eur J Haematol. 2020 Apr;104(4):318-327. doi: 10.1111/ejh.13380. Epub 2020 Jan 20.

CAR T-cell therapy for multiple myeloma: state of the art and prospects.用于多发性骨髓瘤的嵌合抗原受体T细胞疗法：现状与前景

Lancet Haematol. 2021 Jun;8(6):e446-e461. doi: 10.1016/S2352-3026(21)00057-0.

引用本文的文献

Application of the IPDfromKM-Shiny Method to Compare the Efficacy of Novel Treatments Aimed at the Same Disease Condition: A Report of 14 Analyses.应用KM-Shiny方法的个体参与者数据（IPD）比较针对同一疾病状况的新型治疗方法的疗效：14项分析报告

Cancers (Basel). 2023 Mar 7;15(6):1633. doi: 10.3390/cancers15061633.

Outcomes at 5 years in patients with severe aortic stenosis: reviewing current information using the restricted mean survival time.重度主动脉瓣狭窄患者5年的预后：使用受限平均生存时间回顾当前信息。

Am J Cardiovasc Dis. 2020 Aug 15;10(3):136-141. eCollection 2020.

本文引用的文献

Axicabtagene ciloleucel in non-Hodgkin lymphoma: the restricted mean survival time as a tool for estimating progression-free life expectancy better than the median.阿基仑赛治疗非霍奇金淋巴瘤：受限平均生存时间作为一种比中位数更能准确评估无进展预期寿命的工具

Ther Adv Med Oncol. 2020 Jun 3;12:1758835920930643. doi: 10.1177/1758835920930643. eCollection 2020.

Novel Risk Modeling Approach of Atrial Fibrillation With Restricted Mean Survival Times: Application in the Framingham Heart Study Community-Based Cohort.具有受限平均生存时间的心房颤动新型风险建模方法：在弗雷明汉心脏研究社区队列中的应用

Circ Cardiovasc Qual Outcomes. 2020 Apr;13(4):e005918. doi: 10.1161/CIRCOUTCOMES.119.005918. Epub 2020 Mar 31.

Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes.限制平均生存时间的用途和局限性：2 型糖尿病心血管结局和死亡率试验的实例说明。

Ann Intern Med. 2020 Apr 21;172(8):541-552. doi: 10.7326/M19-3286. Epub 2020 Mar 24.

Tisagenlecleucel in Non-Hodgkin Lymphoma: The Restricted Mean Survival Time as a Tool for Estimating Progression-Free Life Expectancy Better than the Median.替沙格赛定在非霍奇金淋巴瘤中的应用：受限平均生存时间作为一种比中位数更能准确估计无进展预期寿命的工具。

Acta Haematol. 2020;143(6):598-599. doi: 10.1159/000505891. Epub 2020 Feb 19.

Using the Restricted Mean Survival Time Difference as an Alternative to the Hazard Ratio for Analyzing Clinical Cardiovascular Studies.使用受限平均生存时间差替代风险比来分析临床心血管研究。

Circulation. 2019 Oct 22;140(17):1366-1368. doi: 10.1161/CIRCULATIONAHA.119.040680. Epub 2019 Oct 21.

Analysis of Survival Curves: Statistical Methods Accounting for the Presence of Long-Term Survivors.生存曲线分析：考虑长期存活者存在情况的统计方法

Front Oncol. 2019 Jun 4;9:453. doi: 10.3389/fonc.2019.00453. eCollection 2019.

Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.使用受限平均生存时间替代风险比来解释癌症临床试验结果的可解释性。

JAMA Oncol. 2017 Dec 1;3(12):1692-1696. doi: 10.1001/jamaoncol.2017.2797.

Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials?受限平均生存时间：癌症试验中事件发生时间分析的必要终点？

J Clin Oncol. 2016 Oct 1;34(28):3474-6. doi: 10.1200/JCO.2016.67.8045. Epub 2016 Aug 9.

Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials.肿瘤学随机对照试验中风险比和受限平均生存时间比测量的治疗效果比较。

J Clin Oncol. 2016 May 20;34(15):1813-9. doi: 10.1200/JCO.2015.64.2488. Epub 2016 Feb 16.

Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies.非劣效性研究中用于比较治疗效果或安全性的风险比替代方法。

Ann Intern Med. 2015 Jul 21;163(2):127-34. doi: 10.7326/M14-1741.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验